Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naive HCV patients in favourable IL28B genotype dominant area
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jin, Y.-J. | - |
dc.contributor.author | Lee, J.-W. | - |
dc.contributor.author | Lee, J.-I. | - |
dc.contributor.author | Park, S.H. | - |
dc.contributor.author | Park, C.K. | - |
dc.contributor.author | Kim, Y.S. | - |
dc.contributor.author | Jeong, S.-H. | - |
dc.contributor.author | Kim, Y.S. | - |
dc.contributor.author | Kim, J.H. | - |
dc.contributor.author | Hwang, S.G. | - |
dc.contributor.author | Rim, K.S. | - |
dc.contributor.author | Yim, H.J. | - |
dc.contributor.author | Cheong, J.Y. | - |
dc.contributor.author | Cho, S.W. | - |
dc.contributor.author | Lee, J.S. | - |
dc.contributor.author | Park, Y.M. | - |
dc.contributor.author | Jang, J.W. | - |
dc.contributor.author | Lee, C.K. | - |
dc.contributor.author | Sohn, J.H. | - |
dc.contributor.author | Yang, J.M. | - |
dc.contributor.author | Han, S. | - |
dc.date.available | 2020-02-29T09:45:12Z | - |
dc.date.created | 2020-02-11 | - |
dc.date.issued | 2012 | - |
dc.identifier.issn | 1948-5964 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/17492 | - |
dc.description.abstract | Background/Aim: Two recent Italian studies suggested that Pegylated-interferon (PEG-IFN) alfa-2a achieves a higher sustained virological response (SVR) rate than PEG-IFN alfa-2b. We intended to compare the efficacy and safety of PEG-IFN alfa-2a with those of PEG-IFN alfa-2b in Korean patients with chronic hepatitis C virus (HCV). Methods: This retrospective, multi-center trial was conducted on 661 treatment-naïve chronic HCV patients. Patients received PEG-IFN alfa-2a (180 μg/week; n=402) or PEG-IFN alfa-2b (1.5 μg/kg/week; n=259) with ribavirin (800-1200 mg/day) for 24 or 48 weeks according to HCV genotypes. Results: Early virological response (EVR), end-of-treatment response (ETR), and SVR rates were not significantly different between two PEG-IFN groups both in patients with HCV genotype 1 (all P-values >0.05) and 2/3 (all P-values >0.05). SVR rates were not different between two groups in each categorized baseline characteristics: age (years) (≤ 50 and >50), HCV viral load (IU/mL) (≤ 7×105 and >7×105), and hepatic fibrosis (F0-2 and F3-4) (all P-values>0.05). In additional analysis for 480 patients who sufficiently complied with treatment doses and duration (80/80/80 rule) and propensity-score matched analysis, SVR rates were not different between two groups both in patients with HCV genotype 1 and 2/3 (all P-values>0.05). Adverse event rates were similar between two groups. Conclusions: Unlike the Western data, efficacy and safety of PEG-IFN alfa-2a were similar to those of PEG-IFN alfa-2b in chronically HCV-infected Korean patients regardless of age, HCV viral load, and hepatic fibrosis. © 2012 Jin YJ, et al. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.relation.isPartOf | Journal of Antivirals and Antiretrovirals | - |
dc.subject | alanine aminotransferase | - |
dc.subject | hemoglobin | - |
dc.subject | interleukin 28B | - |
dc.subject | peginterferon alpha2a | - |
dc.subject | peginterferon alpha2b | - |
dc.subject | ribavirin | - |
dc.subject | adult | - |
dc.subject | alopecia | - |
dc.subject | article | - |
dc.subject | death | - |
dc.subject | drug dose reduction | - |
dc.subject | drug efficacy | - |
dc.subject | drug safety | - |
dc.subject | drug withdrawal | - |
dc.subject | emotional disorder | - |
dc.subject | female | - |
dc.subject | flu like syndrome | - |
dc.subject | follow up | - |
dc.subject | gastrointestinal disease | - |
dc.subject | genotype | - |
dc.subject | hematologic disease | - |
dc.subject | hepatitis C | - |
dc.subject | histology | - |
dc.subject | human | - |
dc.subject | human tissue | - |
dc.subject | infection | - |
dc.subject | Korea | - |
dc.subject | leukocyte count | - |
dc.subject | liver biopsy | - |
dc.subject | liver fibrosis | - |
dc.subject | major clinical study | - |
dc.subject | male | - |
dc.subject | multicenter study | - |
dc.subject | polymerase chain reaction | - |
dc.subject | randomized controlled trial | - |
dc.subject | retrospective study | - |
dc.subject | risk assessment | - |
dc.subject | scoring system | - |
dc.subject | skin manifestation | - |
dc.subject | thrombocyte count | - |
dc.subject | treatment response | - |
dc.subject | virus load | - |
dc.subject | Hepatitis C virus | - |
dc.title | Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naive HCV patients in favourable IL28B genotype dominant area | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.doi | 10.4172/jaa.1000050 | - |
dc.identifier.bibliographicCitation | Journal of Antivirals and Antiretrovirals, v.4, no.4, pp.80 - 87 | - |
dc.identifier.scopusid | 2-s2.0-84871967082 | - |
dc.citation.endPage | 87 | - |
dc.citation.startPage | 80 | - |
dc.citation.title | Journal of Antivirals and Antiretrovirals | - |
dc.citation.volume | 4 | - |
dc.citation.number | 4 | - |
dc.contributor.affiliatedAuthor | Kim, Y.S. | - |
dc.contributor.affiliatedAuthor | Kim, J.H. | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Chronic hepatitis C | - |
dc.subject.keywordAuthor | Pegylated interferon alfa-2a | - |
dc.subject.keywordAuthor | Pegylated interferon alfa-2b | - |
dc.subject.keywordAuthor | Ribavirin | - |
dc.subject.keywordAuthor | Sustained virological response | - |
dc.subject.keywordPlus | alanine aminotransferase | - |
dc.subject.keywordPlus | hemoglobin | - |
dc.subject.keywordPlus | interleukin 28B | - |
dc.subject.keywordPlus | peginterferon alpha2a | - |
dc.subject.keywordPlus | peginterferon alpha2b | - |
dc.subject.keywordPlus | ribavirin | - |
dc.subject.keywordPlus | adult | - |
dc.subject.keywordPlus | alopecia | - |
dc.subject.keywordPlus | article | - |
dc.subject.keywordPlus | death | - |
dc.subject.keywordPlus | drug dose reduction | - |
dc.subject.keywordPlus | drug efficacy | - |
dc.subject.keywordPlus | drug safety | - |
dc.subject.keywordPlus | drug withdrawal | - |
dc.subject.keywordPlus | emotional disorder | - |
dc.subject.keywordPlus | female | - |
dc.subject.keywordPlus | flu like syndrome | - |
dc.subject.keywordPlus | follow up | - |
dc.subject.keywordPlus | gastrointestinal disease | - |
dc.subject.keywordPlus | genotype | - |
dc.subject.keywordPlus | hematologic disease | - |
dc.subject.keywordPlus | hepatitis C | - |
dc.subject.keywordPlus | histology | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | human tissue | - |
dc.subject.keywordPlus | infection | - |
dc.subject.keywordPlus | Korea | - |
dc.subject.keywordPlus | leukocyte count | - |
dc.subject.keywordPlus | liver biopsy | - |
dc.subject.keywordPlus | liver fibrosis | - |
dc.subject.keywordPlus | major clinical study | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | multicenter study | - |
dc.subject.keywordPlus | polymerase chain reaction | - |
dc.subject.keywordPlus | randomized controlled trial | - |
dc.subject.keywordPlus | retrospective study | - |
dc.subject.keywordPlus | risk assessment | - |
dc.subject.keywordPlus | scoring system | - |
dc.subject.keywordPlus | skin manifestation | - |
dc.subject.keywordPlus | thrombocyte count | - |
dc.subject.keywordPlus | treatment response | - |
dc.subject.keywordPlus | virus load | - |
dc.subject.keywordPlus | Hepatitis C virus | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.